Review of TA52; Drugs for early thrombolysis in the treatment of acute myocardial infarction and review of TA230; Bivalirudin for the treatment of ST-segment elevation myocardial infarction (STEMI)

The review date for TA52 guidance was October 2005.  In January 2006, following consultation, the Institute made this guidance 'static'.  The review date for TA230 is July 2014.

The review date is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full appraisal review.

NICE has been asked to develop a clinical guideline on ‘the acute management of myocardial infarction with ST-segment-elevation’ and a related quality standard on the ‘management of acute coronary syndromes including myocardial infarction’. It is proposed that the recommendations of TA52 and TA230 are incorporated verbatim into the clinical guideline.  The guideline developers may supplement the recommendations by placing them in the context of current clinical practice.

It is further proposed that TA230 is moved to the static list and TA52 remains on the static list until such time as the clinical guideline into which they are incorporated is updated. Both technology appraisals will remain extant alongside the clinical guideline. This has the consequence of preserving the funding direction for TA52 and TA230. 

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted. 

June 2012